NMRA
Neumora Therapeutics, Inc. · Healthcare · Market cap $130.0M
Insiders sold $702K net in the last 90 days ·1 seller, 0 buyers· latest Form 4 filed Aug 21, 2026
Insider Buying
$15.0M
reported purchases (SEC code P)
Insider Selling
$1.1M
reported sales (SEC code S)
Unique Insiders
7
in the rolling window
Latest filing
Aug 21, 2026
Aurora Daljit Singh
Neumora Therapeutics, Inc. (NMRA) has 10 SEC Form 4 filings (35 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Aug 21, 2026.
Inside the rolling window, 7 insiders at Neumora Therapeutics, Inc. reported 3 open-market purchases totaling $15.0M and 10 open-market sales totaling $1.1M. The most active filer is See Remarks Aurora Daljit Singh with 7 filings. Insiders have net sold $702K over the trailing 6 months. The most recent open-market filing is a sale of 134,452 shares by See Remarks Aurora Daljit Singh, dated Aug 20, 2026, worth $204K.
- Industry:Biotechnology
- CEO:Paul L. Berns
- Employees:96
- HQ:Watertown, MA, US
- IPO:2023-09-15
| Source | |||||||
|---|---|---|---|---|---|---|---|
| See Remarks | Sale | 134,452 | $204K | Aug 21 | -57.5% | SEC ↗ | |
| See Remarks | Sale | 41,608 | $66K | Aug 21 | -57.5% | SEC ↗ | |
Aurora Daljit SinghFirst in 6 months | See Remarks | Sale | 146,706 | $220K | Aug 19 | -57.8% | SEC ↗ |
Aurora Daljit SinghFirst in 6 months | See Remarks | Sale | 69,149 | $110K | Aug 19 | -57.8% | SEC ↗ |
Aurora Daljit SinghFirst in 6 months | See Remarks | Sale | 61,918 | $102K | Aug 19 | -57.8% | SEC ↗ |
BERNS PAUL LFirst filing | See Remarks | Sale | 9,819 | $34K | Feb 19 | — | SEC ↗ |
Pinto JoshuaFirst filing | President | Sale | 5,967 | $21K | Feb 19 | — | SEC ↗ |
Milligan Michael LeeFirst filing | See Remarks | Sale | 1,436 | $5K | Feb 19 | — | SEC ↗ |
Aurora Daljit SinghFirst in 3 months | See Remarks | Sale | 6,165 | $22K | Feb 19 | — | SEC ↗ |
Aurora Daljit SinghFirst filing | See Remarks | Sale | 114,703 | $307K | Nov 13 | — | SEC ↗ |
ARCH Venture Partners XII, LLCFirst filing | 10% Owner | Purchase | 1,915,700 | $5.0M | Oct 29 | — | SEC ↗ |
ARCH Venture Partners X, LLCFirst filing | 10% Owner | Purchase | 1,915,700 | $5.0M | Oct 29 | — | SEC ↗ |
Burow KristinaFirst filing | Director, 10% Owner | Purchase | 1,915,700 | $5.0M | Oct 29 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does NMRA have?
Neumora Therapeutics, Inc. (NMRA) has 10 SEC Form 4 filings (35 transaction rows) in the rolling 365-day window, disclosed by 7 distinct insiders. Most recent filing: Aug 21, 2026.
When was the most recent SEC Form 4 filing for NMRA?
The most recent Form 4 filing for NMRA on Tracefour is dated Aug 21, 2026.
Who is the most active insider at NMRA?
The most active SEC Form 4 filer at NMRA in the rolling window is See Remarks Aurora Daljit Singh, with 7 filings.
What is the net insider flow at NMRA over the last 6 months?
Over the trailing 180 days, insiders at NMRA have net sold $702K based on SEC Form 4 disclosures.
What is the total insider buy and sell value at NMRA in the current window?
Inside the rolling window, insiders at NMRA bought $15.0M and sold $1.1M based on SEC Form 4 filings.
Can I get alerts for NMRA insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Neumora Therapeutics, Inc. (NMRA). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Neumora Therapeutics, Inc. is in the Healthcare sector.